Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Outlook 2024: Exclusive Report By The Business Research Company

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2398

The Business Research Company offers in-depth market insights through Hypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown steadily in recent years. It will grow from $1.3 billion in 2023 to $1.34 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to diagnostic advancements, increased disease awareness, drug development and approvals, rising healthcare expenditure, government initiatives and funding.

The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.48 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%. The growth in the forecast period can be attributed to genetic research and personalized medicine, emerging therapeutic modalities, collaborative research initiatives, patient-centric healthcare models, lobal health initiatives. Major trends in the forecast period include advancements in targeted therapies, personalized medicine and genetic testing:, drug pipeline expansion, collaborations and partnerships, patient-centric approaches.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=9914&type=smp

Market Segmentation:
The hypertrophic cardiomyopathy (hcm) therapeutics market covered in this report is segmented -

1) By Drug Type: Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types
2) By Device Type: Defibrillators, Pacemakers, Other Device Types
3) By End User: Hospitals, Clinics

Major Driver - Rising Incidence Of Cardiovascular Diseases Fuels Growth In Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
The increasing incidence of cardiovascular diseases (CVD) is expected to propel the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Cardiovascular disease (CVD) is a condition that affects the heart or blood vessels. Cardiovascular diseases include heart irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block that require long-term monitoring. The primary need for therapeutics treatment for hypertrophic cardiomyopathy aims to alleviate symptoms and avoid sudden cardiac death in high-risk patients. For instance, according to the October 2022 report of the Center For Disease Control and Prevention (CDCP), a US-based national public health agency, in the United States, one person dies from cardiovascular disease every 36 seconds, and CVD is responsible for nearly 836,546 deaths in the United States alone in 2021. Therefore, the increasing incidence of cardiovascular diseases (CVD) drives the hypertrophic cardiomyopathy (HCM) therapeutics market.

Competitive Landscape:
Major companies operating in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Merck & Co. Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Correvio Pharma Corp., Abbott Laboratories Inc., Advanz Pharma Corp., Lupin Limited, Myokardia Inc., Boston Scientific Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, Medtronic plc, Mylan N.V., Cardiome Pharma Corp., Cytokinetics Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., HUYA Bioscience International LLC, Ionis Pharmaceuticals Inc., Janssen Pharmaceuticals Inc., Kowa Company Ltd., Luitpold Pharmaceuticals Inc., Menarini Group, Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Servier Laboratories, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited .

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/hypertrophic-cardiomyopathy-hcm-therapeutics-global-market-report

Top Trend - Innovative Products Drive Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
Product innovations are the key trend gaining popularity in the hypertrophic cardiomyopathy (HCM) therapeutics market. Major companies operating in the cardiomyopathy therapeutics sector are focused on developing new innovative products to strengthen their position in the market. For instance, in April 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, launched Camzyos (mavacamten), an oral small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of heart diastolic dysfunction. Camzyos (mavacamten) was approved by the US Food and Drug Administration (FDA) for the treatment of adults with symptomatic class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible inhibitor of cardiac myosin that targets the underlying pathophysiology of obstructive HCM. Camzyos controls the number of myosin heads that can enter "on actin" (power-generating) states.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Characteristics
3. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends And Strategies
4. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market - Macro Economic Scenario
5. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size And Growth
…..
27. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.